>>>NEWS<<<


FREMONT, California, March 31, 2017 – VM Discovery today announced that the Korean Intellectual Property Office (KIPO)
has granted and issued the
Korean Patent No. 10-1723997 to one of its associated companies covering compositions of
compounds and uses thereof
for various disease indications..... <<March 31, 2017>>



FREMONT, California, September 21, 2016 – VM Discovery today announced that the State Intellectual Property Office of The
People’s Republic of China (SIPO) has granted and issued the Chinese Patent Issue No. CN 102177153 B to the Company for
one of its patent applications in China (Application No.: 200980141084.8) covering novel oral selective protein kinase inhibitors
and related compounds for central nervous system disorders, cancer and other disease indications, ... <<September 21, 2016>>



FREMONT, California, May 24, 2016 – VM Discovery today announced that the United States Patent and Trademark Office
(USPTO) has issued the U.S. Patent No. 9,346,788, covering novel composition of selective protein kinase inhibitors to one of
its independent associated companies, VM Oncology.... <<May 24, 2016>>



Stamford, Conn. and Fremont, Calif., September 08, 2015 – Purdue Pharma L.P. announced today the acquisition from VM
Pharma LLC (a spin-off of VM Discovery, Inc.) of VM-902A, a first-in-class, allosteric selective tropomyosin receptor kinase A
(TrkA) inhibitor, as well as the backup compounds and associated intellectual property for the potential treatment of chronic pain.
TrkA is a member of a larger family of important signaling proteins known as tyrosine receptor kinases. Selective inhibition of
TrkA activation provides a new and attractive therapeutic approach to address pain symptoms..... <<
Sept 08, 2015>>



FREMONT, California, July 15, 2015 – VM Discovery today announced that the Japanese Patent Office has grated and issued
the original Letters Patent (No. 5752601) to one of its patent applications covering novel selective protein kinase inhibitors for
treatment of pain, cancer and various diseases. This patent, which covers compounds originally discovered by VM Discovery
and transferred to VM Pharma, a clinical stage drug development company, is entitled "Compositions of Protein Receptor
Tyrosine Kinase Inhibitors".... <<July 15, 2015>>



FREMONT, California, May 26, 2015 – VM Discovery today announced that the United States Patent and Trademark Office
(USPTO) has grated and issued the U.S. Patent No. 9,040,508 to one of its patent applications covering novel oral selective
protein kinase inhibitors and structurally related compounds for pain, cancer and various disease indications. This patent, which
covers compounds originally discovered by VM Discovery and transferred to VM Pharma, a clinical stage drug development
company, is entitled "Compositions of Protein Receptor Tyrosine Kinase Inhibitors".... <<May 26, 2015>>



FREMONT, California, April 07, 2015 – VM Discovery today announced that the United States Patent and Trademark Office
(USPTO) has issued and granted the U.S. Patent No. 8,999,992, covering novel composition and crystalline forms of selective
protein kinase inhibitors and their salts. This patent, which covers compounds originally discovered by VM Discovery and
transferred to VM Pharma, a clinical stage drug development company, will remain in force at least twenty years from the filing
date... <<April 07, 2015>>



FREMONT, California, April 03, 2015 – VM Discovery today announced that the Japanese Patent Office has issued and
granted the Japanese Patent No. 5723600 to one of its patent applications covering the compositions and methods of use of
certain compounds for pain and other diseases or disorders. The patent, which covers compounds originally discovered by VM
Discovery and transferred to VM Therapeutics, is entitled "Method for Treating Pain Syndrome and Other Disorders" and will
remain in force twenty years from the filing date... <<April 03, 2015>>



FREMONT, California, March 17, 2015 – VM Discovery today announced that the United States Patent and Trademark Office
(USPTO) has issued the Issue Notification with U.S. Patent No. 8,980,900 to one of its patent applications covering compounds,
and compositions of certain compounds for pain and other diseases or disorders. The patent, which covers compounds originally
discovered by VM Discovery and transferred to VM Therapeutics, is entitled "Method for Treating Pain Syndrome and
Other Disorders"... <<March 17, 2015>>



FREMONT, California, December, 2014 – VM Discovery today announced that the United States Patent and Trademark Office
(USPTO) has issued the Notice of Allowance for U.S. Application No. 14/208,244 (Track I), for oral selective protein kinase
inhibitors and structurally related compounds for various disease indications. This patent is one of several patent applications
covering compounds originally discovered by VM Discovery and transferred to VM Pharma, a clinical stage drug development
company. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an
application... <<December, 2014>>



FREMONT, California, October 21, 2014 – VM Discovery today announced that the United States Patent and Trademark
Office (USPTO) has issued the Issue Notification with U.S. Patent No. 8,865,727 to one of its patent applications covering
the compositions and methods of use of certain compounds to treat pain syndrome and other disorders. The patent, which is
one of several patent applications covering compounds originally discovered by VM Discovery and transferred to VM
Therapeutics, is entitled "Method for Treating Pain Syndrome and Other Disorders"... <<October 21, 2014>>



FREMONT, California, July/August, 2014 – VM Discovery announced that a highly differentiated drug development program of
orally bioavailable and sub-type selective protein kinase inhibitors has been teamed with VM Oncology, a newly-formed
independent biotech company which is focusing on precision anti-cancer drug development towards human clinical proof of
concept studies. VM Oncology just closed $8M private venture funding from a group of US-based venture investors. The
transaction was closed with legal advice from Cooley LLP... <<July/August, 2014>>



FREMONT, California, July, 2014 – VM Discovery today announced that the State Intellectual Property Office of The People’s
Republic of China (SIPO) has issued the Company Patent Certificate with Patent Issue No. CN 101778563 B, covering
composition of matter and method of use claims for novel apoptosis modulators and structurally related compounds for potential
cancer treatment. This patent is entitled "Compositions and Methods for Apoptosis Modulators" and provides a patent term
which lasts through 2028... <<July, 2014>>



FREMONT, California, May 23, 2014 – VM Discovery today announced that the United States Patent and Trademark Office
(USPTO) has issued the Notice of Allowance with U.S. Patent No. 8,809,530, covering composition of matter and method of use
claims for novel oral protein receptor kinase inhibitors and structurally related compounds for various disease indications. This
patent, which is one of several patent applications covering compounds originally discovered by VM Discovery and transferred to
VM Pharma, a clinical stage drug development company, is entitled "Compositions of Protein Receptor Tyrosine Kinase
Inhibitors". A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an
application... <<May, 2014>>



FREMONT, California, January 13, 2014 – VM Discovery today announced that the United States Patent and Trademark
Office (USPTO) has issued the Notice of Allowance with U.S. Patent No. 8,729,081, covering composition of matter and method
of use claims for novel oral and subtype-selective protein kinase inhibitors for various disease indications. This patent is entitled
"Compositions and Methods for Treating Alcohol Use Disorders, Pain and Other Diseases" and provides a patent term which
may last until 2030 pending patent term adjustment. A Notice of Allowance is issued after the USPTO makes a determination
that a patent can be granted from an application... <<January, 2014>>



FREMONT, California, December 31, 2013 – VM Discovery today announced that the United States Patent and Trademark
Office (USPTO) has issued the U.S. Patent No. 8,618,110, covering composition of matter and method of use claims for novel
apoptosis modulators and structurally related compounds for potential cancer treatment. This patent is entitled "Compositions
and Methods for Apoptosis Modulators" and provides a patent term which lasts through 2028... <<December, 2013>>



FREMONT, California, June 11, 2013 – VM Discovery today announced that the United States Patent and Trademark Office
(USPTO) has issued Notice of Allowance with U.S. Patent No. 8,586,619, covering composition of matter and method of use
claims for novel oral T-type Calcium ion channel modulators and structurally related compounds for various disease indications.
This patent, which was originally discovered by VM Discovery and transferred to VM Therapeutics, is entitled "Agents of
Calcium Ion Channel Modulators" and provides a patent term which may last until 2031 pending patent term adjustment. A
Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application...
<<June, 2013>>



FREMONT, California, September, 2012 – VM Discovery announced that the Company has been awarded a multi-year NIH
translational drug development grant towards IND-enabling drug development for one of its novel oral- and CNS-active, subtype-
selective allosteric kinase inhibitors as a potential first-in-class and best-in-class drug candidate for a CNS disease...
<<September, 2012>>



FREMONT, California, June, 2012 – VM Discovery announced that one of its novel ion channel blocker programs has been
teamed with VM Therapeutics, a newly-formed independent biotech company focusing on drug development towards clinical
proof of concept studies for several disease indications. VM Therapeutics just closed $8M private venture funding from a group
of US-based venture investors. The transaction was closed with legal advice from Cooley LLP... <<June, 2012>>



FREMONT, California, January, 2011 – VM Discovery announced that one of its novel programs of subtype-selective allosteric
receptor tyrosine kinase inhibitors has been teamed with VM Pharma, a newly-formed independent biotech company focusing on
drug development towards clinical proof of concept studies for several disease indications. VM Pharma just closed $8M private
venture funding from a group of US-based venture investors. The transaction was closed with legal advice from Cooley LLP...
<<January, 2011>>



FREMONT, California, November, 2010 – VM Discovery announced that the Company has been awarded a grant in the
amount $244,479 under the Qualifying Therapeutic Discovery Project ("QTDP") program to advance the development of one of
Company's orally bioavailable, subtype-selective allosteric kinase inhibitors as a novel pain therapeutics. The QTDP program  
was created to support innovative medical research by small life sciences companies and to assist in the development of new
therapies to treat areas of unmet medical need; prevent, detect or treat chronic or acute disease and conditions; reduce long-
term health care costs in the U.S., or significantly advance the goal of curing cancer within a 30-year period, as part of the
Patient Protection and Affordable Care Act of 2010. Cash grants were awarded based on a competitive application process after
evaluation by the National Institutes of Health and the Internal Revenue Service. The maximum amount of each grant awarded
under this multi-million dollar program was $244,479. Grants and tax credits were awarded to projects that “show the greatest
potential to create and sustain high-quality, high-paying jobs in the United States and to advance our competitiveness in the
fields of life, biological, and medical sciences.”... <<November, 2010>>



FREMONT, California, September, 2010 – VM Discovery announced that the Company has been awarded a contract from
National Cancer Institute, NIH under the SBIR Topic 255, entitled “Development of Anticancer Agents” to advance the
development of one of Company’s novel orally bioavailable, sub-type selective allosteric kinase inhibitors programs as a
potential novel anticancer therapeutics...<<September, 2010>>



FREMONT, California, October, 2007 – VM Discovery has been awarded ca. $1 Million NIH SBIR II grant for further preclinical
development of one of its small-molecule drug candidates for a CNS Disorder ... <<October, 2007>>



FREMONT, California, March, 2006 – VM Discovery and Fred Hutchinson Cancer Research Center team on cancer drug
discovery ... <<
March, 2006>>



FREMONT, California, January, 2005 – VM Discovery announced that one of seven novel drug candidates designed and
optimized by VM Discovery for a biopharmaceutical company has been entered into a combined human Phase I/II clinical trial
for a cardiovascular disease....<<January, 2005>>



FREMONT, California, August, 2003 – VM Discovery and ChemCodes team on small molecule drug discovery on undisclosed
drug programs ... <<
August, 2003>>



>>>FINANCIAL CONFLICT OF INTEREST POLICY<<<